Barriers to Establishing a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Program without a Pre-Established Bone Marrow Transplant Program

Traditionally, Chimeric Antigen Receptor T-cell (CAR-T) therapy is given at institutions with established bone marrow transplant (BMT) programs due to similarities of treatment and regulations between the two therapies. This can lead to limited access to a critical therapy for patients due to their geographical proximity to these facilities or their ability to travel. To improve access, the administration of CAR-T therapy needs to go beyond institutions with established BMT programs. However, due to high regulations and requirements surrounding CAR-T therapy, establishing a stand-alone CAR-T program is difficult and limited resources exist to aid hospitals in launching these programs.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Mrs. Krystal Waldrup, Ishmael Jaiyesimi, Lauren Burgett, Melissa Pirkola, Mrs. Adelaide van Lier, Annemarie Scanio, Kasey Thayer, Katie Gaches Tags: 436 Source Type: research